Compare Cytokinetics Inc (CYTK) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Global X Robo Global Robotics & Automation ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Global X Robo Global Robotics & Automation ETF trades at $81.26 (market cap $2.06B). The key difference: Cytokinetics Inc is far larger — about 4.2× Global X Robo Global Robotics & Automation ETF's market cap, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Global X Robo Global Robotics & Automation ETF for 36 Days on average.
| CYTK | ROBO | |
|---|---|---|
Market Cap | $8.62B | $2.06B |
Volume | 2,594,626 | 148,111 |
Sector | Health | Sector/Thematic |
52-Week High | $87.26 | $90.34 |
52-Week Low | $54.76 | $63.04 |
Typical Hold Time | 19 Days | 36 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
ROBO trades at $81.26, down 0.68% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong institutional interest in robotics and AI themes, with recent news highlighting accelerating adoption across manufacturing, healthcare, and military applications. Financial ratios are unavailable in the current dataset.
The robotics sector offers long-term growth potential amid labor shortages and AI integration, though high RSI levels suggest near-term overbought conditions. Key risks include valuation concerns and sector competition, while analyst coverage remains favorable for diversified robotics exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
